Clinical Trial Update: Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders [Phase 2]

View source ↗

Summary

Update on a Phase 2 trial of ixabepilone for relapsed or refractory lymphoproliferative disorders (leukemia and lymphoma) indicating the study is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma

Drugs mentioned

• Ixabepilone (Ixempra) (ixabepilone)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED